背景:枫糖浆,一种富含多酚的最低限度转化的甜味剂,可以在动物模型中发挥益生元样作用并改善代谢参数。然而,目前尚无随机临床试验研究枫糖浆替代精制糖对心脏代谢危险因素和肠道菌群组成的影响.
■在随机分组中,双盲,对照交叉试验,对42名超重成年人进行轻度心脏代谢改变,参与者被指示用枫糖浆或人工风味蔗糖糖浆代替总热量摄入的5%,持续8周.主要结果包括葡萄糖稳态的变化,而次要结果是其他心脏代谢危险因素的变化,如血压。人体测量指数,和血脂概况。探索性结果涉及分析肠道微生物群组成的变化。
结果:与用蔗糖糖浆代替精制糖相比,用枫糖浆代替精制糖超过八周可减少曲线下的葡萄糖面积,在口服葡萄糖耐量试验中确定,导致干预组之间存在显着差异(-50.59±201.92vs29.93±154.90,P<.047)。用枫糖浆代替精制糖也显着降低了Android脂肪量(-7.83±175.05对67.61±206.71g,P=0.02)和收缩压(-2.72±8.73vs0.87±8.99mmHg,P=0.03)。未观察到血脂谱的变化。作为一个探索性的结果,我们进一步观察到,用枫糖浆代替精制糖促进了肠道微生物群的选择性分类学变化,例如克雷伯菌的丰度显着降低,并降低了与细菌诱导的细胞因子反应相关的微生物功能。与用蔗糖糖浆代替相比。
结论:在轻度代谢改变的个体中,与用蔗糖糖浆替代相比,用枫糖浆替代精制糖可显著降低关键的心脏代谢危险因素。与肠道微生物群的特定变化有关。肠道微生物群在这些作用中的作用还有待进一步探索。
背景:clinicaltrials.gov为NCT04117802。
BACKGROUND: Maple syrup, a minimally transformed sweetener rich in polyphenols, can exert a action and improve metabolic parameters in animal models. However, no randomized clinical trial has investigated this.
OBJECTIVE: This study aims to determine whether replacing refined sugars with an equivalent quantity of maple syrup could decrease key cardiometabolic risk factors in individuals with mild metabolic alterations.
METHODS: In a randomized, double-blind, controlled crossover trial with 42 overweight adults with mild cardiometabolic alterations, participants were instructed to substitute 5% of their total caloric intake from added sugars with either maple syrup or an artificially flavored sucrose syrup for 8 wk. The primary outcome included changes in glucose homeostasis, whereas secondary outcomes were changes in other cardiometabolic risk factors such as blood pressure, anthropometric indices, and blood lipid profiles. Exploratory outcomes involved analyzing changes in gut microbiota composition.
RESULTS: Replacing refined sugars with maple syrup over 8 wk decreased the glucose area under the curve when compared with substituting refined sugars with sucrose syrup, as determined during the oral glucose tolerance test, leading to a significant difference between the intervention arms (-50.59 ± 201.92 compared with 29.93 ± 154.90; P < 0.047). Substituting refined sugar with maple syrup also significantly decreased android fat mass (-7.83 ± 175.05 g compared with 67.61 ± 206.71 g; P = 0.02) and systolic blood pressure (-2.72 ± 8.73 mm Hg compared with 0.87 ± 8.99 mm Hg; P = 0.03). No changes in the blood lipid profile were observed. As an exploratory outcome, we further observed that substituting refined sugars with maple syrup promoted selective taxonomic changes in the gut microbiota such as a significant reduction in the abundance of Klebsiella species and decreased microbial functions associated with bacterial-induced cytokine response, when compared with substitution with sucrose syrup.
CONCLUSIONS: Substituting refined sugars with maple syrup in individuals with mild metabolic alterations result in a significantly greater reduction of key cardiometabolic risk factors compared with substitution with sucrose syrup, in association with specific changes in gut microbiota. The role of the gut microbiota in these effects remains to be further explored. This trial was registered at clinicaltrials.gov as NCT04117802.